| Drug ID: | Drug177 |
|---|---|
| Drug Name: | Valganciclovir |
| CID: | 135413535 |
| DrugBank ID: | DB01610 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00237653, , NCT04064697 |
| Molecular Formula: | C14H22N6O5 |
| Molecular Weight: | 354.36 g/mol |
| Isomeric SMILES: | CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N |
| Synonyms: | Valganciclovir; 175865-60-8; UNII-GCU97FKN3R; GCU97FKN3R; CHEBI:63635; HSDB 8085; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; DTXSID8048288; Ro-1079070/194; L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester |
| Phase 0: | 0 |
| Phase 1: | 17 |
| Phase 2: | 33 |
| Phase 3: | 35 |
| Phase 4: | 18 |
| Description: | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1289 | 135413535 | Valganciclovir | 2703462 | UL30 | Human alphaherpesvirus 1 strain 17 | 37713619 | Inhibitor |
| dt1290 | 135413535 | Valganciclovir | 6564 | SLC15A1 | Homo sapiens (human) | 10824137 | None |
| dt1291 | 135413535 | Valganciclovir | 6565 | SLC15A2 | Homo sapiens (human) | 10824137 | None |
| dt1292 | 135413535 | Valganciclovir | 11254 | SLC6A14 | Homo sapiens (human) | 15290873 | None |
| dt1293 | 135413535 | Valganciclovir | 670 | BPHL | Homo sapiens (human) | 15832508 | BPHL protein results in increased hydrolysis of valganciclovir |
| dt1294 | 135413535 | Valganciclovir | 6564 | SLC15A1 | Homo sapiens (human) | 10824137 | SLC15A1 protein results in increased transport of valganciclovir|valganciclovir inhibits the reaction [SLC15A1 protein results in increased transport of glycylsarcosine] |
| dt1295 | 135413535 | Valganciclovir | 6565 | SLC15A2 | Rattus norvegicus (Norway rat) | 10824137 | Valganciclovir inhibits the reaction [SLC15A2 protein results in increased transport of glycylsarcosine] |
| dt1296 | 135413535 | Valganciclovir | 2703462 | UL30 | Human alphaherpesvirus 1 strain 17 | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT04064697 | Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy | PHASE3 | TERMINATED | Centre Hospitalier Universitaire de Saint Etienne | Ulcerative Colitis, Unspecified | DRUG: Valganciclovir | Details |
| NCT00237653 | MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus | PHASE3 | TERMINATED | University Hospital, Grenoble | Cytomegalovirus Infections|Inflammatory Bowel Dis… | DRUG: Valganciclovir | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations